{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:12:10Z","timestamp":1788516730800,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Juvenile Myelomonocytic Leukemia (JMML) is an aggressive pediatric hematological cancer categorized by aberrant activation of the RAS\/MAPK pathway. It is commonly caused by gain-of-function mutations, such as E76K in the PTPN11 protein. While 5-azacitidine (5-Aza) and the MEK inhibitor PD0325901 (PD-901) are not known direct inhibitors of SHP2\/PTPN11, the reported activity of 5-Aza combined with MEK inhibition in PTPN11-mutated JMML offered a biological rationale for examining their potential structural interactions with SHP2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used a computational approach that included molecular docking, molecular dynamics (MD) simulations, and binding free-energy calculations using the MM-PBSA method to exploratively investigate interactions between 5-azacitidine (5-Aza) and the MEK inhibitor PD0325901 (PD-901) with wild-type and E76K-mutant PTPN11 proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the molecular docking study, 5-Aza was observed to bind within the active site, whereas PD-901 bound preferentially to the allosteric site. The dual-ligand simulations were used to investigate whether occupancy of these distant regions was associated with changes in PTPN11's structural and dynamic characteristics. MD simulations showed that the structures of all complexes remained stable throughout, and that the combined structure exhibited lower deviations, less residue flexibility, compactness, and more intermolecular hydrogen-bond interactions. Principal component analysis also revealed differences in the dominant conformational motions of the ligand-bound systems. MM-PBSA calculations provided comparative estimates of binding energetics and revealed promising interaction energies for all complexes, particularly in the E76K mutant system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, these computational findings suggest that the association of 5-Aza and PD-901 with distinct regions of PTPN11 may influence its structural and dynamic properties. These findings should therefore be considered exploratory and do not establish direct SHP2 binding or inhibition by either compound. Further biochemical, biophysical, and cellular studies are needed to validate these predicted interactions and determine their potential biological or therapeutic relevance in JMML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2026.1887328","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:14:46Z","timestamp":1788513286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational insights into synergistic mechanisms of PD-901 and 5-azacitidine targeting PTPN11 (SHP2) E76K mutation in juvenile myelomonocytic leukemia"],"prefix":"10.3389","volume":"6","author":[{"given":"Abeer M.","family":"Al-Subaie","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balu","family":"Kamaraj","sequence":"additional","affiliation":[{"name":"Department of Dental Education, College of Dentistry, Imam Abdulrahman Bin Faisal University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","volume-title":"GROMACS User Manual Version 5.0. 4","author":"Abraham","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1107\/s0907444902003451","article-title":"The protein data bank","volume":"58","author":"Berman","year":"2002","journal-title":"Biol. Crystallogr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/bloodadvances.2020002123","article-title":"Role of lncRNA morrbid in PTPN11 (Shp2) E76K-driven juvenile myelomonocytic leukemia","volume":"4","author":"Cai","year":"2020","journal-title":"Blood Adv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2012","journal-title":"J. Clinical Investigation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1101\/2024.05.16.594555","article-title":"In vivo targeting MEK and TNK2\/SRC pathways in PTPN11 driven leukemia","volume":"18","author":"Chang","year":"2024","journal-title":"bioRxiv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood-2015-01-619734","article-title":"Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group","volume":"125","author":"Cseh","year":"2015","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1736501","DOI":"10.3389\/fbinf.2026.1736501","article-title":"Integrated molecular dynamics elucidation of TP53 H179 zinc-binding variants: genomic and structural characterization across NSCLC subtypes","volume":"6","author":"Datta","year":"2026","journal-title":"Front. Bioinforma."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1021\/acs.jmedchem.3c02118","article-title":"Fragment-based discovery of allosteric inhibitors of SH2 domain-containing protein tyrosine phosphatase-2 (SHP2)","volume":"67","author":"Day","year":"2024","journal-title":"J. Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29930","DOI":"10.1002\/pbc.29930","article-title":"Targeted therapy in juvenile myelomonocytic leukemia: where are we now?","volume":"69","author":"De Vos","year":"2022","journal-title":"Pediatr. Blood & Cancer"},{"key":"B10","volume-title":"The Pymol Molecular Graphics System","author":"DeLano","year":"2002"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/cancers14051335","article-title":"Genomic and epigenomic landscape of juvenile myelomonocytic leukemia","volume":"14","author":"Fi\u00f1ana","year":"2022","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1080\/07391102.2019.1667265","article-title":"Structural insights of metallo-beta-lactamase revealed an effective way of inhibition of enzyme by natural inhibitors","volume":"38","author":"Gangadharappa","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: an advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminformatics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1182\/blood-2021-149324","article-title":"Small molecule kinase inhibitor sunitinib specifically targets juvenile myelomonocytic leukemia cells with SHP2 (PTPN11) mutation","volume":"138","author":"He","year":"2021","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"115588","DOI":"10.1016\/j.bcp.2023.115588","article-title":"Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia","volume":"213","author":"He","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9144","DOI":"10.3390\/ijms26189144","article-title":"Exploring the therapeutic potential of Epigallocatechin-3-gallate (green tea) in periodontitis using network pharmacology and molecular modeling approach","volume":"26","author":"Kamaraj","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10822-025-00601-8","article-title":"Theoretical investigation of AKT1 mutations in breast cancer: a computational approach to structural and functional insights","volume":"39","author":"Kamaraj","year":"2025","journal-title":"J. Computer-Aided Mol. Des."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1142\/s2737416525500115","article-title":"Computational analysis of mutations in WNT10A gene and its structural and functional consequences in tooth agenesis","volume":"24","author":"Kamaraj","year":"2025","journal-title":"J. Comput. Biophysics Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14728222.2022.2066518","article-title":"Targeting SHP2 phosphatase in hematological malignancies","volume":"26","author":"Kanumuri","year":"2022","journal-title":"Expert Opinion Therapeutic Targets"},{"key":"B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/bib\/2.2.195","article-title":"Swiss-PDB viewer (deep view)","volume":"2","author":"Kaplan","year":"2001","journal-title":"Briefings Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/17460441.2016.1216967","article-title":"Getting the most out of PubChem for virtual screening","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opinion Drug Discovery"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"G_mmpbsa - a GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chemical Information Modeling"},{"key":"B23","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Medicinal Chemistry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104391","DOI":"10.1016\/j.bioorg.2020.104391","article-title":"Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation","volume":"105","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1271268","DOI":"10.3389\/fphar.2023.1271268","article-title":"Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1510896","DOI":"10.3389\/fmolb.2025.1510896","article-title":"Computational molecular insights into ibrutinib as a potent inhibitor of HER2-L755S mutant in breast cancer: gene expression studies, virtual screening, docking, and molecular dynamics analysis","volume":"12","author":"Loganathan","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"76ra27","DOI":"10.1126\/scitranslmed.3001069","article-title":"A MEK inhibitor abrogates myeloproliferative disease in kras mutant mice","volume":"3","author":"Lyubynska","year":"2011","journal-title":"Sci. Translational Medicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.3390\/jcm10143084","article-title":"Current treatment of juvenile myelomonocytic leukemia","volume":"10","author":"Mayerhofer","year":"2021","journal-title":"J. Clin. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100652","DOI":"10.1016\/j.blre.2020.100652","article-title":"After 95 years, it's time to eRASe JMML","volume":"43","author":"Meynier","year":"2020","journal-title":"Blood Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1182\/bloodadvances.2020004144","article-title":"Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial","volume":"5","author":"Niemeyer","year":"2021","journal-title":"Blood Advances"},{"key":"B31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminformatics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"130503","DOI":"10.1016\/j.molstruc.2021.130503","article-title":"Structural, hirshfeld, spectroscopic, quantum chemical and molecular docking studies of N'-(4-(4-Chlorophenyl)-1, 3-dicyano-5, 6, 7, 8, 9, 10-hexahydrobenzo [8] annulen 2-yl) N, N-dimethylformimidamide as CCR2 inhibitors","volume":"1239","author":"Pangajavalli","year":"2021","journal-title":"J. Mol. Struct."},{"key":"B33","volume-title":"Targeting M2-tumor Associated Macrophages by arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse","author":"Pasupuleti","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2023.01.030","article-title":"Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia","volume":"31","author":"Pasupuleti","year":"2023","journal-title":"Mol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1182\/blood-2024-209744","article-title":"CD39, CD73 and the adenosine pathway mediate immune escape in juvenile myelomonocytic leukemia (JMML)","volume":"144","author":"Rajak","year":"2024","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.ymthe.2022.04.009","article-title":"Inhibition of BTK and PI3K\u03b4 impairs the development of human JMML stem and progenitor cells","volume":"30","author":"Ramdas","year":"2022","journal-title":"Mol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"112117","DOI":"10.1016\/j.ejmech.2020.112117","article-title":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","volume":"190","author":"Shen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.3390\/cancers15215204","article-title":"Epigenetic profiling of PTPN11 mutant JMML hematopoietic stem and progenitor cells reveals an aberrant histone landscape","volume":"15","author":"Sinha","year":"2023","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e73040","DOI":"10.7554\/elife.73040","article-title":"Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects","volume":"11","author":"Solman","year":"2022","journal-title":"Elife"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2021-144850","article-title":"MEK inhibition demonstrates activity in relapsed, refractory patients with juvenile myelomonocytic leukemia: results from COG study ADVL1521","volume":"138","author":"Stieglitz","year":"2021","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Computational Chemistry"},{"key":"B42","first-page":"649","volume-title":"Discovery Studio Visualizer","author":"Visualizer","year":"2005"},{"key":"B43","first-page":"2001","article-title":"Antechamber: an accessory software package for molecular mechanical calculations","volume":"222","author":"Wang","year":"2001","journal-title":"J. Am. Chem. Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-20-1365","article-title":"Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Research"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/ddr.22100","article-title":"Allosteric modulation of SHP2: quest from known to unknown","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.3390\/cells10092335","article-title":"Induced pluripotent stem cells to model juvenile myelomonocytic leukemia: new perspectives for preclinical research","volume":"10","author":"Wehbe","year":"2021","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/bs.acr.2023.03.003","article-title":"Setting sail: maneuvering SHP2 activity and its effects in cancer","volume":"160","author":"Welsh","year":"2023","journal-title":"Adv. Cancer Research"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1080\/07391102.2020.1726817","article-title":"Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors","volume":"39","author":"Wu","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41375-023-02079-5","article-title":"BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia","volume":"38","author":"Wu","year":"2024","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Medicinal Chemistry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1080\/07391102.2024.2431193","article-title":"Prediction of SHP2-E76K binding sites based on molecular dynamics simulation and markov algorithm","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1182\/blood-2021-150007","article-title":"Establishment of stable cell lines representing juvenile myelomonocytic leukemia with SHP2 mutations","volume":"138","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40164-023-00379-1","article-title":"Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML","volume":"12","author":"Zhao","year":"2023","journal-title":"Exp. Hematol. & Oncol."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2026.1887328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:14:48Z","timestamp":1788513288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2026.1887328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":53,"alternative-id":["10.3389\/fbinf.2026.1887328"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2026.1887328","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1887328"}}